ainsliadimer A: a sesquiterpene lactone dimer with an unusual carbon skeleton from Ainsliaea macrocephala; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ainsliadimer A : A sesquiterpene lactone isolated from the whole plants of Ainsliaea macrocephala; exhibits inhibitory activity against production of nitric oxide (NO). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Ainsliaea | genus | [no description available] | Asteraceae | A large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 24939147 |
| CHEMBL ID | 4877539 |
| CHEBI ID | 65376 |
| SCHEMBL ID | 17214370 |
| MeSH ID | M0523521 |
| Synonym |
|---|
| ainsliadimer a |
| (+)-ainsliadimer a |
| (3as,3a's,6ar,6a'r,7a's,9r,9ar,9bs,10a's,10b's,10c's)-7a',10a'-dihydroxy-3,3',6,6'-tetramethylideneicosahydro-2h-spiro[azuleno[4,5-b]furan-9,8'-cyclopenta[2,3]azuleno[4,5-b]furan]-2,2',8(3h,3'h)-trione |
| CHEBI:65376 |
| SCHEMBL17214370 |
| Q27133821 |
| ofp6ez7dzu , |
| ainsliadimer a [mi] |
| unii-ofp6ez7dzu |
| 1039431-94-1 |
| (3as,3'as,6ar,6'ar,7'as,8'r,9ar,9bs,10'as,10'bs,10'cs)-eicosahydro-7'a,10'a-dihydroxy-3,3',6,6'-tetrakis(methylene)spiro(azuleno(4,5-b)furan-9(2h),8'-(8h)cyclopent(2,3)azuleno(4,5-b)furan)-2,2',8(3h,3'h)-trione |
| spiro(azuleno(4,5-b)furan-9(2h),8'-(8h)cyclopent(2,3)azuleno(4,5-b)furan)-2,2',8(3h,3'h)-trione, eicosahydro-7'a,10'a-dihydroxy-3,3',6,6'-tetrakis(methylene)-, (3as,3'as,6ar,6'ar,7'as,8'r,9ar,9bs,10'as,10'bs,10'cs)- |
| spiro[azuleno[4,5-b]furan-9(2h),8'-[8h]cyclopent[2,3]azuleno[4,5-b]furan]-2,2',8(3h,3'h)-trione, eicosahydro-7'a,10'a-dihydroxy-3,3',6,6'-tetrakis(methylene)-, (3as,3'as,6ar,6'ar,7'as,8'r,9ar,9bs,10'as,10'bs,10'cs)- |
| CHEMBL4877539 |
| DTXSID001098274 |
| (3as,3'as,6ar,6'ar,7'as,8'r,9ar,9bs,10'as,10'bs,10'cs)-eicosahydro-7'a,10'a-dihydroxy-3,3',6,6'-tetrakis(methylene)spiro[azuleno[4,5-b]furan-9(2h),8'-[8h]cyclopent[2,3]azuleno[4,5-b]furan]-2,2',8(3h,3'h)-trione |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| EC 1.14.13.39 (nitric oxide synthase) inhibitor | An EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor that interferes with the action of nitric oxide synthase (EC 1.14.13.39). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| spiro compound | A compound having one atom as the only common member of two rings. |
| sesquiterpene lactone | Any member of a diverse class of complex, multicyclic phytochemicals showing a variety of skeleton arrangements and bioactivities, and having in common a sesquiterpenoid structure including a lactone ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1773822 | Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 72 hrs by Celltiter-Glo assay | 2021 | Journal of natural products, 09-24, Volume: 84, Issue:9 | Cytotoxic Guaianolide Sesquiterpenoids from |
| AID1773821 | Cytotoxicity against rat C6 cells assessed as reduction in cell viability incubated for 72 hrs by Celltiter-Glo assay | 2021 | Journal of natural products, 09-24, Volume: 84, Issue:9 | Cytotoxic Guaianolide Sesquiterpenoids from |
| AID1773823 | Cytotoxicity against human HCCLM3 cells assessed as reduction in cell viability incubated for 72 hrs by Celltiter-Glo assay | 2021 | Journal of natural products, 09-24, Volume: 84, Issue:9 | Cytotoxic Guaianolide Sesquiterpenoids from |
| AID1773824 | Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability incubated for 72 hrs by Celltiter-Glo assay | 2021 | Journal of natural products, 09-24, Volume: 84, Issue:9 | Cytotoxic Guaianolide Sesquiterpenoids from |
| AID1773825 | Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by Celltiter-Glo assay | 2021 | Journal of natural products, 09-24, Volume: 84, Issue:9 | Cytotoxic Guaianolide Sesquiterpenoids from |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.85) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||